Global Pegfilgrastim Biosimilars Market Trends And Strategies Of Major Players In The Pegfilgrastim Biosimilars Market 2021-2030

2 Dec, 2021

Check out TBRC’s sale today for

The pegfilgrastim biosimilars market consists of the sales of pegfilgrastim biosimilars and related services offered by the companies that develop and manufacture them. Pegfilgrastim is a version of filgrastim (Neupogen), used to increase the production of infection-fighting white blood cells for the treatment of cancer patients undergoing chemotherapy. Pegfilgrastim biosimilars find their applications in reducing infection for patients undergoing anticancer therapy.

Global Pegfilgrastim Biosimilars Market Size And Drivers:

The global pegfilgrastim biosimilars market is expected to grow from $0.80 billion in 2020 to $0.88 billion in 2021 at a compound annual growth rate (CAGR) of 10%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The pegfilgrastim biosimilars market is expected to reach $1.42 billion in 2025 at a CAGR of 13%. Government initiatives for the development of biosimilars are expected to drive the pegfilgrastim biosimilars.

Request For A Sample For The Global Pegfilgrastim Biosimilars Market Report:

Trends In The Global Pegfilgrastim Biosimilars Market

Companies in the pegfilgrastim biosimilar market are increasing their product innovation through strategic collaborations. To sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with each other as well as academic and research institutions in this market by way of partnerships, in or out licensing deals, this trend has been increasing over the recent years. For instance, in July 2018, Fulphila, co-developed by Biocon Biologics and Mylan, was the first biosimilar pegfilgrastim to be approved by the FDA.

Global Pegfilgrastim Biosimilars Market Segments:
The global pegfilgrastim biosimilars market is further segmented –
By Application: Chemotherapy Treatment, Transplantation, Others
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies
By Geography: The global pegfilgrastim biosimilars market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa.

Read More On The Report For The Global Pegfilgrastim Biosimilars Market At:

Pegfilgrastim Biosimilars Global Market Report 2021 is one of a series of new reports from The Business Research Company that provides pegfilgrastim biosimilars market overviews, analyzes and forecasts market size and growth for the global pegfilgrastim biosimilars market, pegfilgrastim biosimilars market share, pegfilgrastim biosimilars market players, pegfilgrastim biosimilars market segments and geographies, pegfilgrastim biosimilars market’s leading competitors’ revenues, profiles and market shares. The pegfilgrastim biosimilars market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.

Call Us

+1 3156230293


+44 2071930708


+91 8897263534

(Asia & Others)